Phase III trial of triple therapy is initiated for VX 445, tezacaftor and ivacaftor to treat F508del mutation cystic fibrosis.- Vertex Pharma.
Vertex Pharmaceuticals Incorporated announced that it is initiating two Phase III studies of VX 445, tezacaftor and ivacaftor as an investigational triple combination regimen for people with cystic fibrosis (CF). The first Phase III study will evaluate approximately 360 people with CF who have one copy of the F508del mutation and one minimal function mutation and is designed to support the submission of a New Drug Application (NDA) in the U.S. using data from the study�s 4-week primary efficacy endpoint together with safety data through 12 weeks of treatment. The second Phase III study will evaluate approximately 100 people with CF who have two copies of the F508del mutation, the most common genetic form of the disease, and is designed to support the submission of an application for approval in patients with two copies of the F508del mutation in the U.S. using data from the study�s 4-week primary efficacy endpoint together with 24-week safety data generated from the Phase III study in patients with one F508del mutation and one minimal function mutation.
The initiation of the study in people with two copies of the F508del mutation is supported by data announced from a Phase II study that showed an incremental mean absolute improvement in percent predicted forced expiratory volume in one second (ppFEV1) of 11.0 percentage points from baseline through week four of treatment when VX 445 (200 mg) was added in people with CF who have two F508del mutations and were already receiving tezacaftor in combination with ivacaftor. In the Phase II study, the VX 445 triple combination regimen was generally well tolerated, and the majority of adverse events were mild to moderate in severity.
Comment: Vertex plans Phase III trials of its next-generation correctors VX 659 and VX 445. They will be part of two triple combination therapy regimens that Vertex tests in CF patients. The combinations have the potential to treat patients with mutations that fail to respond to VX 661 (tezacaftor) or Kalydeco (ivacaftor).
Related news and insights
Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), announced that Health Canada has approved Ferriprox (deferiprone) for the treatment of iron overload in patients with sickle cell disease (SCD) or other anemias.
The Menarini Group and Radius Health announced positive topline results from the phase III EMERALD study evaluating RAD 1901 (elacestrant) as a monotherapy versus the standard of care (SoC) for the treatment of ER+/HER2- advanced or metastatic breast cancer (mBC).
Gilead Sciences, Inc. announced the FDA approved a new low-dose tablet dosage form of Biktarvy (bictegravir 30 mg/emtricitabine 120 mg/tenofovir alafenamide 15 mg tablets) for pediatric patients weighing at least 14 kg to less than 25 kg who are virologically suppressed or new to antiretroviral therapy.